Suppression of follicular phase pituitary-gonadal function by a potent new gonadotropin-releasing hormone antagonist with reduced histamine-releasing properties (ganirelix).

Nelson LR, Fujimoto VY, Jaffe RB, Monroe SE

Fertility and sterility1 May 1995Cited by 34 (Europe PMC)

PMID7536693DOI10.1016/s0015-0282(16)57531-1PepBankPUB-07536693

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanNon-randomized trialEfficacy outcome
In ovulatory women, ganirelix 1 mg rapidly decreased serum gonadotropins.
In plain wordsIn ovulatory women, ganirelix 1 mg rapidly decreased blood gonadotropins from baseline.
Peptide
Ganirelix
Outcome
DecreaseGonadotropin levels
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
1 mg · subcutaneous · 8 daysAs given in this study (human).
Source sentences
Summary
Ganirelix treatment rapidly decreased serum levels of gonadotropins and E2 after both 1 and 2 mg administration.
3 context sentences(design, population, supporting numbers)
Summary · context
Open-label nonrandomized clinical study.
Summary · context
Women 21 to 45 years of age, with documented ovulatory menstrual cycles.
Summary · context
Ganirelix was administered subcutaneously daily for 8 days.
Report a problemFND-0753669301
02HumanNon-randomized trialEfficacy outcome
In ovulatory women, ganirelix 2 mg rapidly decreased serum gonadotropins.
In plain wordsIn ovulatory women, ganirelix 2 mg rapidly decreased blood gonadotropins from baseline.
Peptide
Ganirelix
Outcome
DecreaseGonadotropin levels
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
2 mg · subcutaneous · 8 daysAs given in this study (human).
Source sentences
Summary
Ganirelix treatment rapidly decreased serum levels of gonadotropins and E2 after both 1 and 2 mg administration.
3 context sentences(design, population, supporting numbers)
Summary · context
Open-label nonrandomized clinical study.
Summary · context
Women 21 to 45 years of age, with documented ovulatory menstrual cycles.
Summary · context
Ganirelix was administered subcutaneously daily for 8 days.
Report a problemFND-0753669302
03HumanNon-randomized trialEfficacy outcome
In ovulatory women, estradiol fell from 50 ± 8 to 25 ± 4 pg/mL twenty-four hours after ganirelix 1 mg.
In plain wordsIn ovulatory women, estradiol decreased from baseline twenty-four hours after ganirelix 1 mg.
Peptide
Ganirelix
Outcome
DecreaseEstradiol after first dose
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
1 mg · subcutaneous · 8 daysAs given in this study (human).
Measurements
Estradiol
50 pg/mL
1 mg group, baseline; SEM 8
Estradiol
25 pg/mL
1 mg group, 24 hours after first dose; SEM 4
Source sentences
Summary
Twenty-four hours after the first dose of ganirelix, E2 decreased from a mean +/- SEM of 50 +/- 8 and 67 +/- 11 pg/mL at baseline to 25 +/- 4 and 20 +/- 3 in the 1 mg and 2 mg groups, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
Open-label nonrandomized clinical study.
Summary · context
Women 21 to 45 years of age, with documented ovulatory menstrual cycles.
Summary · context
Ganirelix was administered subcutaneously daily for 8 days.
Report a problemFND-0753669303
04HumanNon-randomized trialEfficacy outcome
In ovulatory women, estradiol fell from 67 ± 11 to 20 ± 3 pg/mL twenty-four hours after ganirelix 2 mg.
In plain wordsIn ovulatory women, estradiol decreased from baseline twenty-four hours after ganirelix 2 mg.
Peptide
Ganirelix
Outcome
DecreaseEstradiol after first dose
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
2 mg · subcutaneous · 8 daysAs given in this study (human).
Measurements
Estradiol
67 pg/mL
2 mg group, baseline; SEM 11
Estradiol
20 pg/mL
2 mg group, 24 hours after first dose; SEM 3
Source sentences
Summary
Twenty-four hours after the first dose of ganirelix, E2 decreased from a mean +/- SEM of 50 +/- 8 and 67 +/- 11 pg/mL at baseline to 25 +/- 4 and 20 +/- 3 in the 1 mg and 2 mg groups, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
Open-label nonrandomized clinical study.
Summary · context
Women 21 to 45 years of age, with documented ovulatory menstrual cycles.
Summary · context
Ganirelix was administered subcutaneously daily for 8 days.
Report a problemFND-0753669304
05HumanNon-randomized trialEfficacy outcome
In ovulatory women, mean estradiol remained below 26 pg/mL during the subsequent 7 days of ganirelix 1 mg dosing.
In plain wordsIn ovulatory women, estradiol remained suppressed during subsequent ganirelix 1 mg dosing.
Peptide
Ganirelix
Outcome
DecreaseSustained estradiol suppression
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
1 mg · subcutaneous · 8 daysAs given in this study (human).
Measurements
Mean estradiol
< 26 pg/mL
1 mg group, subsequent 7 days of dosing
Source sentences
Summary
Estradiol remained suppressed (mean levels < 26 pg/mL) on all subsequent 7 days of ganirelix dosing in both groups.
4 context sentences(design, population, supporting numbers)
Summary · context
Twenty-four hours after the first dose of ganirelix, E2 decreased from a mean +/- SEM of 50 +/- 8 and 67 +/- 11 pg/mL at baseline to 25 +/- 4 and 20 +/- 3 in the 1 mg and 2 mg groups, respectively.
Summary · context
Open-label nonrandomized clinical study.
Summary · context
Women 21 to 45 years of age, with documented ovulatory menstrual cycles.
Summary · context
Ganirelix was administered subcutaneously daily for 8 days.
Report a problemFND-0753669305
06HumanNon-randomized trialEfficacy outcome
In ovulatory women, mean estradiol remained below 26 pg/mL during the subsequent 7 days of ganirelix 2 mg dosing.
In plain wordsIn ovulatory women, estradiol remained suppressed during subsequent ganirelix 2 mg dosing.
Peptide
Ganirelix
Outcome
DecreaseSustained estradiol suppression
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
2 mg · subcutaneous · 8 daysAs given in this study (human).
Measurements
Mean estradiol
< 26 pg/mL
2 mg group, subsequent 7 days of dosing
Source sentences
Summary
Estradiol remained suppressed (mean levels < 26 pg/mL) on all subsequent 7 days of ganirelix dosing in both groups.
4 context sentences(design, population, supporting numbers)
Summary · context
Twenty-four hours after the first dose of ganirelix, E2 decreased from a mean +/- SEM of 50 +/- 8 and 67 +/- 11 pg/mL at baseline to 25 +/- 4 and 20 +/- 3 in the 1 mg and 2 mg groups, respectively.
Summary · context
Open-label nonrandomized clinical study.
Summary · context
Women 21 to 45 years of age, with documented ovulatory menstrual cycles.
Summary · context
Ganirelix was administered subcutaneously daily for 8 days.
Report a problemFND-0753669306
07HumanNon-randomized trialEfficacy outcome
In ovulatory women, ovarian function returned rapidly in all volunteers after the final ganirelix dose.
In plain wordsIn ovulatory women, ovarian function returned rapidly after ganirelix stopped.
Peptide
Ganirelix
Outcome
Not applicableOvarian function recovery
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
1 mg or 2 mg daily · subcutaneous · 8 daysAs given in this study (human).
Source sentences
Summary
After the final dose of ganirelix, there was a rapid return of ovarian function in all volunteers.
3 context sentences(design, population, supporting numbers)
Summary · context
Open-label nonrandomized clinical study.
Summary · context
Women 21 to 45 years of age, with documented ovulatory menstrual cycles.
Summary · context
Ganirelix was administered subcutaneously daily for 8 days.
Report a problemFND-0753669307
08HumanNon-randomized trialEfficacy outcome
In ovulatory women, all participants had progesterone levels indicating ovulation in the cycle after ganirelix.
In plain wordsIn ovulatory women, all participants had hormone levels indicating ovulation in the cycle after ganirelix.
Peptide
Ganirelix
Outcome
Not applicableOvulation in subsequent cycle
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
1 mg or 2 mg daily · subcutaneous · 8 daysAs given in this study (human).
Source sentences
Summary
All women had P levels indicative of ovulation in the subsequent cycle, and the mean number of days from the final ganirelix dose to the next menses was 25.8 +/- 2.1 and 27.3 +/- 1.6 in the 1 and 2 mg groups, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
Open-label nonrandomized clinical study.
Summary · context
Women 21 to 45 years of age, with documented ovulatory menstrual cycles.
Summary · context
Ganirelix was administered subcutaneously daily for 8 days.
Report a problemFND-0753669308
09HumanNon-randomized trialEfficacy outcome
In ovulatory women, next menses occurred a mean 25.8 ± 2.1 days after the final ganirelix 1 mg dose.
In plain wordsIn ovulatory women, next menses occurred a mean 25.8 days after the final ganirelix 1 mg dose.
Peptide
Ganirelix
Outcome
Not applicableTime to next menses
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
1 mg · subcutaneous · 8 daysAs given in this study (human).
Measurements
Days from final dose to next menses
25.8 days
1 mg group; ± 2.1
Source sentences
Summary
All women had P levels indicative of ovulation in the subsequent cycle, and the mean number of days from the final ganirelix dose to the next menses was 25.8 +/- 2.1 and 27.3 +/- 1.6 in the 1 and 2 mg groups, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
Open-label nonrandomized clinical study.
Summary · context
Women 21 to 45 years of age, with documented ovulatory menstrual cycles.
Summary · context
Ganirelix was administered subcutaneously daily for 8 days.
Report a problemFND-0753669309
10HumanNon-randomized trialEfficacy outcome
In ovulatory women, next menses occurred a mean 27.3 ± 1.6 days after the final ganirelix 2 mg dose.
In plain wordsIn ovulatory women, next menses occurred a mean 27.3 days after the final ganirelix 2 mg dose.
Peptide
Ganirelix
Outcome
Not applicableTime to next menses
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
2 mg · subcutaneous · 8 daysAs given in this study (human).
Measurements
Days from final dose to next menses
27.3 days
2 mg group; ± 1.6
Source sentences
Summary
All women had P levels indicative of ovulation in the subsequent cycle, and the mean number of days from the final ganirelix dose to the next menses was 25.8 +/- 2.1 and 27.3 +/- 1.6 in the 1 and 2 mg groups, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
Open-label nonrandomized clinical study.
Summary · context
Women 21 to 45 years of age, with documented ovulatory menstrual cycles.
Summary · context
Ganirelix was administered subcutaneously daily for 8 days.
Report a problemFND-0753669310

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.